TIGIT and neoplasm: Thibaudin et al. assessed the potential of combining atezolizumab (anti-PD-L1) and tiragolumab (anti-TIGIT) to reinvigorate the immune response of tumor-infiltrating lymphocytes in microsatellite-stable (MSS) colorectal cancer [106].